Immunization

One vaccine dosing regimen for AZD1222 showed 90% efficacy, according to investigators at the University of Oxford.

Pfizer and BioNTech expect to produce up to 50 million doses globally in 2020 and up to 1.3 billion doses by the end of 2021.

Pfizer and BioNTech today announced that their COVID-19 vaccine candidate showed a 95% efficacy rate in the final analysis of its phase 3 study.

Moderna announced today that its messenger RNA vaccine candidate for COVID-19 met the primary endpoint of efficacy, according to the study’s first interim analysis.

As part of a new partnership with HHS, the nation’s largest pharmacy chains—as well as independents and regional chains—will be administering free coronavirus disease 2019 (COVID-19) vaccines when they are available.

The FDA has granted Fast Track Designation for NVX-CoV2373, a vaccine candidate for COVID-19.

Interim analysis results from a phase 3 clinical trial reported a vaccine efficacy rate above 90% for BNT162b2. The trial is ongoing until it meets its threshold for confirmed COVID-19 cases.

Pharmacies are seeing an increased demand for flu vaccines in the first season that coincides with the coronavirus pandemic.

Here’s a preview of the featured content to watch for this week on Drug Topics®.

Robert Hopkins, chair of the National Vaccine Advisory Committee, discusses the most pressing issues coming out of the recent NVAC meeting and pharmacy's role amid the COVID-19 pandemic.

Robert Hopkins, chair of the National Vaccine Advisory Committee, discusses the most pressing issues coming out of the recent NVAC meeting, and pharmacy's role amid the COVID-19 pandemic.

CMS’ new plan will ensure coverage of COVID-19 vaccines with no out-of-pocket costs, while increasing the number of providers that will administer the vaccine.

Study suggests review of current recommendations.

Of the nearly 3 million Americans included in the study, just 1.4% had the flu vaccine and 1.4% had the pneumonia vaccine.

The program is designed to prepare state-licensed pharmacists to meet requirements for administering vaccinations to pediatric patients.

A poster at the virtual 2020 ID Week looked at how vaccine type can impact diphtheria, tetanus, and acellular pertussis (DTaP) vaccination.

Investigators stressed that governments, public health officials, and other non-governmental organizations should aim to build trust in a COVID-19 vaccine.

Here's the coronavirus-related news from this week that you should know.

The combined landscape of flu and COVID-19 presents challenges to vaccine uptake.

The new guidance provides clarification on requirements for pharmacy interns and technicians to administer childhood and COVID-vaccines, as well as COVID-19 tests.

In an open letter, Pfizer Chairman and CEO wrote that safety and efficacy data for its COVID-19 vaccine candidate may be ready by the third week of November for FDA submission.

The BCG vaccine decreased the overall risk of new respiratory infections in elderly adults, according to the study results.

A new report from the National Academies of Sciences, Engineering, and Medicine include pharmacists in the priority group for receiving the COVID-19 vaccine when available.

Amid this unprecedented flu season, experts recommend co-administering flu and shingles vaccines.

Moderna’s COVID-19 mRNA vaccine candidate appears to induce as strong an immune response in older adults as in younger adults, according to an interim analysis.